DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Serentil (Mesoridazine Besylate) - Summary

 
 



WARNING

SERENTIL® (MESORIDAZINE BESYLATE) HAS BEEN SHOWN TO PROLONG THE QTc INTERVAL IN A DOSE RELATED MANNER, AND DRUGS WITH THIS POTENTIAL, INCLUDING SERENTIL, HAVE BEEN ASSOCIATED WITH TORSADE DE POINTES-TYPE ARRHYTHMIAS AND SUDDEN DEATH. DUE TO ITS POTENTIAL FOR SIGNIFICANT, POSSIBLY LIFE-THREATENING, PROARRHYTHMIC EFFECTS, SERENTIL SHOULD BE RESERVED FOR USE IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS WHO FAIL TO SHOW AN ACCEPTABLE RESPONSE TO ADEQUATE COURSES OF TREATMENT WITH OTHER ANTIPSYCHOTIC DRUGS, EITHER BECAUSE OF INSUFFICIENT EFFECTIVENESS OR THE INABILITY TO ACHIEVE AN EFFECTIVE DOSE DUE TO INTOLERABLE ADVERSE EFFECTS FROM THOSE DRUGS. (SEE WARNINGS, CONTRAINDICATIONS, AND INDICATIONS.)

 

SERENTIL SUMMARY

Serentil®

SERENTIL® (mesoridazine besylate), the besylate salt of a metabolite of thioridazine, is a phenothiazine antipsychotic. Serentil is 10-[2(1-methyl-2-piperidyl)ethyl]-2-(methyl-sulfinyl)-phenothiazine [as the besylate].

Serentil® (mesoridazine besylate) is indicated for the management of schizophrenic patients who fail to respond adequately to treatment with other antipsychotic drugs. Due to the risk of significant, potentially life-threatening, proarrhythmic effects with Serentil treatment, Serentil should be used only in patients who have failed to respond adequately to treatment with appropriate courses of other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs. Consequently, before initiating treatment with Serentil, it is strongly recommended that a patient be given at least two trials, each with a different antipsychotic drug product at an adequate dose, and for an adequate duration (see WARNINGS and CONTRAINDICATIONS).

      However, the prescriber should be aware that Serentil has not been systematically evaluated in controlled trials in treatment of refractory schizophrenic patients and its efficacy in such patients is unknown.


See all Serentil indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Serentil (Mesoridazine)

Discovery of novel drug target may lead to better treatment for schizophrenia
Source: Psychology / Psychiatry News From Medical News Today [2014.12.12]
Scientists at the Centre for Addiction and Mental Health (CAMH) have identified a novel drug target that could lead to the development of better antipsychotic medications.Dr.

FDA Okays Aripiprazole for Acute Schizophrenia Relapse
Source: Medscape Psychiatry & Mental Health Headlines [2014.12.08]
The FDA has approved a labeling update for the long-acting injectable antipsychotic aripiprazole.
News Alerts

Study Finds Need for Improved Schizophrenia Care
Source: MedicineNet Schizophrenia Specialty [2014.12.04]
Title: Study Finds Need for Improved Schizophrenia Care
Category: Health News
Created: 12/4/2014 12:00:00 AM
Last Editorial Review: 12/4/2014 12:00:00 AM

Excess protein during brain development causes abnormalities and faulty connections in laboratory studies, may trigger schizophrenia
Source: Schizophrenia News From Medical News Today [2014.11.26]
A gene associated with schizophrenia plays a role in brain development and may help to explain the biological process of the disease, according to new Rutgers research.

Brain network vulnerable to Alzheimer's and schizophrenia identified
Source: MRI / PET / Ultrasound News From Medical News Today [2014.11.25]
A specific brain network within grey matter develops later than the rest of the brain and degenerates first in older age, says new study, shedding light on neurological disorders.

more news >>

Published Studies Related to Serentil (Mesoridazine)

Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses. [2007.11]
We compared the effects of single doses of thioridazine and mesoridazine on the heart rate-corrected QT (QTc) interval in healthy adult volunteers. QTc intervals and plasma concentrations of thioridazine, mesoridazine, and metabolites were measured after single oral doses of thioridazine hydrochloride 50 mg, mesoridazine besylate 50 mg, or placebo in a double-blind, crossover study...

more studies >>

Clinical Trials Related to Serentil (Mesoridazine)

Reducing Antipsychotic-Induced Weight Gain in Children With Metformin [Recruiting]
Recent but limited short term studies have shown that Metformin can slow down weight gain in obese children and in children with psychotropic-induced weight gain, two distinct pediatric populations that are at risk for obesity related co-morbid conditions. The purpose of this study is to conduct a long term prospective pilot cohort study to investigate the use of Metformin to prevent or decrease weight gain in two cohorts of children: 1) children with psychotropic induced weight gain on Metformin and 2) children with BMI above the 95th percentile on Metformin. Both study populations will be enrolled in a lifestyle weight management program

more trials >>


Page last updated: 2014-12-12

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014